Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Tyligand Bio Files Hong Kong IPO with Phase II KRAS G12D Inhibitor TSN1611

Fineline Cube Jan 30, 2026
Company Deals

Genhouse Bio Files Hong Kong IPO with Phase II SHP2 Inhibitor GH21

Fineline Cube Jan 30, 2026
Company Deals

CSPC Pharma Signs $18.5B AstraZeneca Deal for Weight Management Portfolio

Fineline Cube Jan 30, 2026
Company Deals

Fosun Pharma Licenses HPV DNA Drug VGX-3100 from ApolloBio for Greater China

Fineline Cube Jan 29, 2026
Company Deals

Kanghua to Acquire NanoRibo in Phased Deal for mRNA Platform

Fineline Cube Jan 29, 2026
Policy / Regulatory

FDA Removes Suicide Warnings from GLP‑1 Drugs After Investigation Finds No Causal Link

Fineline Cube Jan 28, 2026
Company Drug

China Medical’s Opzelura Cream Gets NMPA Approval for Vitiligo

Fineline Cube Jan 30, 2026
Company Drug

Zhaoke Ophthalmology’s Yuvezzi Gets FDA Nod for Presbyopia

Fineline Cube Jan 30, 2026
Company

Lonza Announces Factory Closures in the US and China Amid Global Network Optimization

Fineline Cube Jan 29, 2024

Swiss Contract Manufacturing Organization (CMO) Lonza has released its 2023 financial report, which includes plans...

Company Policy / Regulatory

China-Based Biotechs Respond to US House Bill Limiting Federal Funding for ‘Concerning’ Companies

Fineline Cube Jan 29, 2024

A bipartisan bill introduced on January 26, 2024, by members of the US House Select...

Company Drug

Eisai’s Alzheimer’s Drug Leqembi Earns Marketing Approval in China

Fineline Cube Jan 28, 2024

Eisai (TYO: 4523), a leading Japanese pharmaceutical company, has announced that it has received marketing...

Company Deals

Wuxi National Hi-Tech District Welcomes Synthetic Biology Industrial Park and East China’s First R&D Center

Fineline Cube Jan 26, 2024

The Wuxi National Hi-Tech District (WND) has welcomed the opening of a new synthetic biology...

Company Deals

Kingmed Diagnostics and MegaRobo Technologies Join Forces to Pioneer Smart Medical Laboratories

Fineline Cube Jan 26, 2024

Kingmed Diagnostics (SHA: 603882), a prominent independent medical laboratory headquartered in Guangdong, is poised to...

Company Drug

Henlius Biotech Ships First International Batch of HanSiZhuang for Cancer Treatment to Indonesia

Fineline Cube Jan 26, 2024

Shanghai Henlius Biotech Inc., (HKG: 2696), a leading biotech company from China, has announced the...

Company Drug

Shanghai Fosun Pharmaceutical Receives NMPA Approval for Phase II Study of FCN-338 for Light Chain Amyloidosis

Fineline Cube Jan 26, 2024

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading pharmaceutical company based...

Company Deals

MSD Partners with Variational AI to Harness Generative AI for Drug Discovery

Fineline Cube Jan 26, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK) has embarked on a collaborative project with Canadian...

Company Drug

Gan & Lee Pharmaceuticals Receives Bolivian Approval for Insulin Aspart, Expanding Access to Rapid-Acting Insulin

Fineline Cube Jan 26, 2024

Gan & Lee Pharmaceuticals (SHA: 603087), a Chinese pharmaceutical company, has announced that it has...

Policy / Regulatory

China’s NHC Designates 100 Areas as National Demonstration Zones for Integrated Medical and Elderly Care

Fineline Cube Jan 26, 2024

The National Health Commission (NHC) has announced the selection of 100 counties (cities, districts), including...

Company Drug

Roche Commences Phase II Trial of Repare Therapeutics’ ATR Inhibitor, Camonsertib, in Solid Tumors

Fineline Cube Jan 26, 2024

Swiss pharmaceutical giant Roche (SWX: ROG) has reached a significant milestone this week with the...

Company Drug

Roche’s Tecentriq in Combination with Exelixis’s Cabometyx Meets Primary Endpoint in mCRPC Phase III Study

Fineline Cube Jan 26, 2024

Roche (SWX: ROG), the Swiss pharmaceutical giant, has announced positive results from a Phase III...

Company Drug

Pfizer’s Nurtec Approved by China’s NMPA for Acute Treatment of Migraines

Fineline Cube Jan 26, 2024

Pfizer Inc. (NYSE: PFE), a leading pharmaceutical company in the U.S., has announced that it...

Company Drug

Novo Nordisk’s Rybelsus Approved for Type 2 Diabetes in China, Setting New Oral Treatment Standard

Fineline Cube Jan 26, 2024

Novo Nordisk (NYSE: NVO), a major Danish pharmaceutical company, has received approval from China’s National...

Company

BJ Bioscience Inc. Faces Bankruptcy as Hangzhou Court Accepts Liquidation Application

Fineline Cube Jan 25, 2024

The Hangzhou Yuhang District People’s Court has released a document indicating that BJ Bioscience Inc.’s...

Company

Wantai Biological Forecasts Sharp Drop in 2023 Net Profits Amid HPV Vaccine Sales Slump

Fineline Cube Jan 25, 2024

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd (SHA: 603392), a Chinese pharmaceutical company, has issued...

Company Drug

Eli Lilly’s Subsidiary Akouos Reports Positive Preliminary Results for Gene Therapy in Hearing Loss

Fineline Cube Jan 25, 2024

Eli Lilly (NYSE: LLY) has announced preliminary results from a Phase I/II study conducted by...

Company Deals R&D

Shanghai Pharmaceuticals and HKSTPC Launch 01LABS@Hong Kong Incubator

Fineline Cube Jan 25, 2024

01LABS@Hong Kong, a Shanghai-Hong Kong innovation incubator, has officially commenced operations. The incubator was jointly...

Company Drug

Biosion’s SIRPα-Targeting Monoclonal Antibody BSI-082 Clears US FDA Clinical Trial Hurdle

Fineline Cube Jan 25, 2024

Biosion, a global clinical-stage biotechnology company dedicated to developing antibody-based therapies for immune and oncologic...

Company Drug

IASO Biotherapeutics Secures NMPA Approval for Fucaso in Refractory Myasthenia Gravis

Fineline Cube Jan 25, 2024

China-based IASO Biotherapeutics has received clinical trial approval from the National Medical Products Administration (NMPA)...

Posts pagination

1 … 359 360 361 … 617

Recent updates

  • China Medical’s Opzelura Cream Gets NMPA Approval for Vitiligo
  • Zhaoke Ophthalmology’s Yuvezzi Gets FDA Nod for Presbyopia
  • CSPC’s SYS 6055 CAR-T Gets NMPA Nod for Lymphoma Trials
  • AstraZeneca Commits $14.4B China Investment in Cell Therapy Push
  • Ascletis ASC40 Phase III Success in Acne Vulgaris
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

China Medical’s Opzelura Cream Gets NMPA Approval for Vitiligo

Company Drug

Zhaoke Ophthalmology’s Yuvezzi Gets FDA Nod for Presbyopia

Company Drug

CSPC’s SYS 6055 CAR-T Gets NMPA Nod for Lymphoma Trials

Company

AstraZeneca Commits $14.4B China Investment in Cell Therapy Push

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.